DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...
But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom ...
Progress in medicine could lead to a smaller target market for DexCom. However, the company is expanding opportunities through innovation. On the other hand, DexCom has attractive opportunities that ...
Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results